Dr Stromatt replaces Daniel Burge who will be resigning his position with the company for personal reasons in late August 2008.
Most recently, Dr Stromatt was executive vice president of clinical and regulatory affairs at Cell Therapeutics in Seattle. Before holding this role at Cell Therapeutics, Dr Stromatt was vice president of clinical research and chief medical officer at Northwest Biotherapeutics in Bothell, Washington.
Peter Thompson, president, CEO and chairman of Trubion, said: “Dr Stromatt’s experience, particularly in the area of rheumatology and oncology drug development, is a great fit for Trubion as we continue to expand our product pipeline and develop new product candidates.”